Immucell Corp(ICCC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | 122.29 | EPS (ttm) | 0.08 | Insider Own | 37.62% | Shs Outstand | 9.1M | Perf Week | 0.1% |
| Market Cap | 0.09B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.23% | Shs Float | 5.7M | Perf Month | 6.88% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | - | Inst Own | 15.14% | Short Float | 0.32% | Perf Quarter | -7.07% |
| Income | 0.00B | P/S | 3.04 | EPS this Y | - | Inst Trans | -0.97% | Short Ratio | 1 | Perf Half Y | 17.53% |
| Sales | 0.03B | P/B | 2.97 | EPS next 5Y | - | ROA | 1.69% | Short Interest | 0.02M | Perf YTD | 66.83% |
| Book/sh | 3.45 | P/C | 10.52 | EPS past 3/5Y | 29.01% 4.06% | ROE | 2.57% | 52W High | -15.21% ($12.10) | Perf Year | 68.47% |
| Cash/sh | 0.98 | P/FCF | 22.13 | Sales past 3/5Y | 14.19% 12.5% | ROIC | 1.87% | 52W Low | 126.99% ($4.52) | Perf 3Y | 108.11% |
| Dividend Est. | - | EV/EBITDA | 22.77 | EPS Y/Y TTM | -54.03% | Gross Margin | 40.32% | Volatility(W/M) | 2.24% 2.25% | Perf 5Y | 16.59% |
| Dividend TTM | - | EV/Sales | 3.15 | Sales Y/Y TTM | 8.49% | Oper. Margin | 6.08% | ATR (14) | 0.3 | Perf 10Y | 82.35% |
| Dividend Ex-Date | - | Quick Ratio | 2.71 | EPS Q/Q | 258.99% | Profit Margin | 2.57% | RSI (14) | 50.49 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.75 | Sales Q/Q | 11.5% | SMA20 | -0.04% ($10.26) | Beta | 0.62 | Target Price | - |
| Payout | - | Debt/Eq | 0.4 | Earnings | 2026/8/13 | SMA50 | 2.21% ($10.04) | Rel Volume | 0.61 | Prev Close | $10.32 |
| Employees | 73 | LT Debt/Eq | 0.34 | EPS/Sales Surpr. | - | SMA200 | 15.78% ($8.86) | Avg Volume(3M) | 0.02M | Price | $10.26 |
| IPO | 1987/5/5 | Option/Short | No/Yes | Trades | 169 | Volume | 11,025 | Change | -0.58% |
🐄 Elanco (ticker: ELAN) is an animal healthcare company that improves the health and productivity of dairy and beef cattle. The company develops, manufactures, and sells oral immunity products to prevent diarrhea (scours) in newborn calves, as well as diagnostic and therapeutic products for dairy cow mastitis, primarily operating in the US market.
Over the past 1 year, on the higher side
15% below its 1-year high.
Traded less than usual. That is 61% of its average volume.
ICCC earns at a steady pace
Of every $100 in sales, $6.08 is kept as operating profit.
Tap to view numbers
However, it looks expensive
Counting its debt, for $100 of yearly operating cash you would pay $2,277. Peers typically go for $2,000. It is about in line with its own 1-year average.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +16.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 15.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #366 of 597 in the industry
Based on market cap of $93M.
RTSN#363 Retension Pharmaceuticals Inc $95M PER - 
GNLX#364 Genelux Corp $94M PER - 
NTHI#365 NeOnc Technologies Holdings Inc $94M PER - ICCC#366 Immucell Corp $93M PER 122.3 
SEER#367 Seer Inc $93M PER - 
FAQ
What kind of company is ICCC?
ICCC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ICCC?
The market cap of ICCC is approximately $93M, ranking 4,501 within its sector.
What is the P/E ratio of ICCC?
ICCC has a P/E ratio of approximately 122.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ICCC?
ICCC has recorded a 52-week high of $12.10 and a low of $4.52.
